Trial Profile
A 4-Week, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Potential of Topically Applied 0.75% (w/w) MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2014
Price :
$35
*
At a glance
- Drugs MTC 896 (Primary)
- Indications Seborrhoeic dermatitis
- Focus Therapeutic Use
- Sponsors Mimetica
- 11 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Apr 2014 New trial record